This week we were pleased to learn that GSK had ranked highest in the Access to Medicines Index for 2010. It's an honor to be acknowledged for our focus on generating, and delivering, new initiatives to improve lives around the world.
We are proud of our initiatives to improve affordability and to conduct and encourage more investment in R&D for diseases of the developing world. Yet we know that, despite significant progress over the last decade, there is more work to be done.
Read about what GSK is doing to improve innovation and access to medicines for the developing world and emerging markets and watch a clip of Andrew Witty's interview today on "Power Lunch" at CNBC.com.
Leave a comment